MedTrace Logo

Folate Receptor in Diagnosing Ovarian Cancer Using Serum Samples From Patients With Newly Diagnosed Pelvic Mass or Previously Diagnosed Ovarian Cancer

NCT02520115 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2019-08-14

No results posted yet for this study

Summary

This pilot research trial studies folate receptor in diagnosing ovarian cancer using serum samples from patients with a newly diagnosed pelvic mass or previously diagnosed ovarian cancer. Studying samples of serum from patients with ovarian cancer in the laboratory may help understand the use of folate receptor induction as a clinical tool in initial diagnosis, surveillance, and recurrence.

Conditions

  • Adnexal Mass
  • Borderline Ovarian Epithelial Tumor
  • Ovarian Clear Cell Tumor
  • Ovarian Endometrioid Tumor
  • Ovarian Neoplasm
  • Ovarian Serous Tumor
  • Recurrent Ovarian Carcinoma

Interventions

DRUG

Dexamethasone

Given PO

OTHER

Laboratory Biomarker Analysis

Analysis of serum and tissue samples

DRUG

Valproic Acid

Given PO

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Barbara Ann Karmanos Cancer Institute

    lead OTHER

Principal Investigators

  • Ira Winer · Barbara Ann Karmanos Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2018-09-30
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02520115 on ClinicalTrials.gov